Drugs /

obrindatamab

Back to Drugs List
Associated Genetic Biomarkers

Overview

NCI Definition [1]:
An Fc-bearing humanized bispecific dual-affinity re-targeting (DART) protein composed of Fv regions derived from monoclonal antibodies against the immunoregulatory protein B7-homologue 3 (B7-H3, CD276) and the T-cell surface antigen CD3, with potential immunostimulating and antineoplastic activities. Upon administration of obrindatamab, the anti-B7-H3 component targets and binds to the cell surface antigen B7-H3; at the same time, the anti-CD3 component binds to human CD3. This cross-links the T-cells to B7-H3-expressing tumor cells, activates and redirects endogenous T-cells to kill B7-H3-expressing tumor cells, and inhibits proliferation of B7-H3-expressing tumor cells. B7-H3, a type I transmembrane protein and a member of the B7 co-stimulatory protein superfamily, is overexpressed on certain tumor cell types and on various immune cells but is minimally expressed by normal human tissues. B7-H3 is a negative regulator of T-cell activation and its overexpression plays a key role in immuno-evasion, tumor cell invasion and metastasis, and its expression is correlated with poor prognosis.

Clinical Trials

View Clinical Trials for obrindatamab

Obrindatamab has been investigated in 2 clinical trials, of which 1 is open and 1 is closed. Of the trials investigating obrindatamab, 2 are phase 1 (1 open).

CD276 Expression is the most frequent biomarker inclusion criterion for obrindatamab clinical trials.

Malignant solid tumor is the most common disease being investigated in obrindatamab clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Obrindatamab
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Obrindatamab
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating obrindatamab and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
b7-h3 x cd3 dual-affinity re-targeting protein mgd009, dart protein mgd009, mgd009, dual-affinity b7-h3/cd3-targeted protein mgd009
Drug Categories [2]:
Immunotherapies
Drug Target(s) [2]:
CD276, CD3
NCIT ID [1]:
C136983

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.